Effects of rose hip intake on risk markers of type 2 diabetes and cardiovascular disease: a randomized, double-blind, cross-over investigation in obese persons.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Abstract

BACKGROUND/OBJECTIVES:In studies performed in mice, rose hip powder has been shown to both prevent and reverse high-fat diet-induced obesity and glucose intolerance as well as reduce plasma levels of cholesterol. The aim of this study was to investigate whether daily intake of rose hip powder over 6 weeks exerts beneficial metabolic effects in obese individuals.SUBJECTS/METHODS:A total of 31 obese individuals with normal or impaired glucose tolerance were enrolled in a randomized, double-blind, cross-over study in which metabolic effects of daily intake of a rose hip powder drink over 6 weeks was compared with a control drink. Body weight, glucose tolerance, blood pressure, blood lipids and markers of inflammation were assessed in the subjects.RESULTS:In comparison with the control drink, 6 weeks of daily consumption of the rose hip drink resulted in a significant reduction of systolic blood pressure (-3.4%; P=0.021), total plasma cholesterol (-4.9%; P=0.0018), low-density lipoprotein (LDL) cholesterol (-6.0%; P=0.012) and LDL/HDL ratio (-6.5%; P=0.041). The Reynolds risk assessment score for cardiovascular disease was decreased in the rose hip group compared with the control group (-17%; P=0.007). Body weight, diastolic blood pressure, glucose tolerance, and plasma levels of high-density lipoprotein (HDL) cholesterol, triglycerides, incretins and markers of inflammation did not differ between the two groups.CONCLUSIONS:Daily consumption of 40 g of rose hip powder for 6 weeks can significantly reduce cardiovascular risk in obese people through lowering of systolic blood pressure and plasma cholesterol levels.European Journal of Clinical Nutrition advance online publication, 14 December 2011; doi:10.1038/ejcn.2011.203.

Detaljer

Författare
Enheter & grupper
Forskningsområden

Ämnesklassifikation (UKÄ) – OBLIGATORISK

  • Annan klinisk medicin
  • Endokrinologi och diabetes
Originalspråkengelska
Sidor (från-till)585-590
TidskriftEuropean Journal of Clinical Nutrition
Volym66
Utgivningsnummer5
StatusPublished - 2012
PublikationskategoriForskning
Peer review utfördJa

Related projects

Patrick Adlercreutz, Irini Lazou Ahrén, Siv Ahrné, Said Alhamimi, Kristina E Andersson, Kristina E Andersson, Anna Månberger, Ulrika Axling, Ulrika Axling, Björn Bergenståhl, Karin Berger, Inger Björck, Camilla Bränning, Fredrik Bäckhed, Yoghatama Cindya Zanzer, Anders Danielsson, Birgitta Danielsson, Eva Degerman, Petr Dejmek, Estera Dey, Anestis Dougkas, Linda Ekström, Ann-Charlotte Eliasson, Christer Fahlgren, Peter Falck, Peter Falck, Tannaz Ghaffarzadegan, Yvonne Granfeldt, Carl Grey, Ulrika Gunnerud, Åsa Håkansson, Åsa Håkansson, Frida Hållenius, Frida Hållenius, Lina Haskå, Lina Haskå, Emilia Heimann, Per Hellstrand, Lovisa Heyman, Cecilia Holm Wallenberg, Ann-Kristin Holmén-Pålbrink, Olle Holst, Tina Immerstrand, Peter Immerzeel, Greta Jakobsdottir, Bengt Jeppsson, Elin Johansson, Maria Johansson, Maria Johansson, Margareta Johansson, Ulla Johansson, Helena Jones, E N Karlsson, Petia Kovatcheva-Datchary, Evelina Kulcinskaja, Mona Landin-Olsson, Caroline Linninge, Ali Marefati, Nittaya Marungruang, Göran Molin, Anne Nilsson, Einar Nilsson, Ulf Nilsson, Margareta Nyman, Eva Ohlson, Crister Olsson, Rickard Öste, Elin Östman, Lisbeth Persson, Stefan Persson, Merichel Plaza, Olena Prykhodko, Karl Radeborg, Marilyn Rayner, Liza Rosén, Margareta Sandahl, Jonna Sandberg, Malin Sjöö, Kerstin Skog, Peter Spégel, Henrik Stålbrand, Olov Sterner, Julia Svensson, Eden Tareke, Juscelino Tovar, Charlotta Turner, Björn Weström, Jie Xu & Yadong Zhong

2007/07/012018/01/31

Projekt: Forskning

Visa alla (1)